What is the price-to-earnings ratio of Insmed?
The price-earnings ratio of Insmed is currently 21.61.
Insmed P/S 2024
Insmed P/S
21.61
Ticker
INSM
ISIN
US4576693075
WKN
A1JJA3
As of Sep 12, 2024, Insmed's P/S ratio stood at 21.61, a 144.18% change from the 8.85 P/S ratio recorded in the previous year.
The Insmed P/S history
Insmed Aktienanalyse
What does Insmed do?
Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Insmed's P/S Ratio
Insmed's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Insmed's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Insmed's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Insmed’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Insmed stock
How has the price-earnings ratio of Insmed changed compared to last year?
The price-to-earnings ratio of Insmed has increased by 144.18% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Insmed high compared to other companies?
Yes, the price-to-earnings ratio of Insmed is high compared to other companies.
How does an increase in the price-earnings ratio of Insmed affect the company?
An increase in the price-earnings ratio of Insmed would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Insmed affect the company?
A decrease in the price-earnings ratio of Insmed would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Insmed?
Some factors that influence the price-earnings ratio of Insmed are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Insmed pay?
Over the past 12 months, Insmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Insmed is expected to pay a dividend of 0 USD.
What is the dividend yield of Insmed?
The current dividend yield of Insmed is .
When does Insmed pay dividends?
Insmed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Insmed?
Insmed paid dividends every year for the past 0 years.
What is the dividend of Insmed?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Insmed located?
Insmed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Insmed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Insmed from 9/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did Insmed pay the last dividend?
The last dividend was paid out on 9/12/2024.
What was the dividend of Insmed in the year 2023?
In the year 2023, Insmed distributed 0 USD as dividends.
In which currency does Insmed pay out the dividend?
The dividends of Insmed are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Insmed
Our stock analysis for Insmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Insmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
